Jason A. Efstathiou, MD, DPhil, FASTRO, FACRO, presented “Advances in Treating the Primary and Sites of Metastases in Oligometastatic Prostate Cancer” during the 24th Future Directions in Urology Symposium in August 2024 in Colorado Springs, Colorado.
How to cite: Efstathiou, Jason A. “Advances in Treating the Primary and Sites of Metastases in Oligometastatic Prostate Cancer.” August 2024. Accessed Oct 2024. https://grandroundsinurology.com/advances-in-treating-the-primary-and-sites-of-metastases-in-oligometastatic-prostate-cancer/
Advances in Treating the Primary and Sites of Metastases in Oligometastatic Prostate Cancer – Summary
Jason A. Efstathiou, MD, DPhil, FASTRO, FACRO, highlights the evolving landscape of prostate cancer management, emphasizing the impact of new data, technologies, and clinical trials. A key focus is on the role of radiation therapy in treating metastatic and oligometastatic prostate cancer, particularly in combination with systemic therapies such as androgen deprivation therapy (ADT) and next-generation agents like abiraterone.
In this 11-minute presentation, Dr. Efstathiou reviews studies like the STAMPEDE and the P1 trials, suggesting that radiation combined with intensified systemic therapy can delay disease progression. The presentation also highlights advancements in imaging, such as trials like STOMP and ORIOLE.
Dr. Efstathiou emphasizes the integration of advanced imaging and genomics into clinical practice, allowing better patient selection and risk stratification. The discussion touches on the importance of multidisciplinary care to ensure optimal treatment strategies, particularly as prostate cancer management becomes increasingly complex.
The Future Directions in Urology Symposium (FDUS) is an annual urology think tank and non-CME educational summit that brings together industry figures and experts to discuss the current state of genitourinary care and define future directions in treatment. Dr. Dreicer delivered this educational activity during the 24th iteration of the meeting in August 2024 in Colorado Springs, Colorado.
ABOUT THE AUTHOR
Jason A. Efstathiou, MD, DPhil, is Professor of Radiation Oncology at Harvard Medical School (HMS) as well as Director of the Genitourinary (GU) Division in the Department of Radiation Oncology and Clinical Co-Director of the Claire and John Bertucci Center for GU Cancers at Massachusetts General Hospital. He is a recognized leader in the fields of GU malignancies and radiation oncology. Dr. Efstathiou holds a BS from Yale University, an MD from Harvard Medical School, and a DPhil from the University of Oxford. He completed his residency training through the Harvard Radiation Oncology Program.
Dr. Efstathiou’s research has informed clinical guidelines and made novel contributions to innovations such as organ preservation therapy for bladder cancer, technology assessment of proton beam therapy for prostate cancer, indications for and adverse effects of androgen deprivation therapy for prostate cancer, improving radiation therapy for testicular cancer, and global oncology outreach efforts.
In addition to his educational work and his patient care, Dr. Efstathiou holds leadership positions within cooperative groups and professional societies
